Vir Biotechnology (VIR) announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta. ECLIPSE 1 is one of three trials in Vir Biotechnology’s ECLIPSE registrational program for CHD, and it is designed to provide the efficacy and safety data needed for potential submission to global regulatory agencies, including in the U.S. and Europe. Enrollment in the other two trials in the program, ECLIPSE 2 and ECLIPSE 3, is ongoing and on track. The last patient in ECLIPSE 1 is expected to reach the trial’s primary endpoint in the fourth quarter of 2026, with topline data expected in the first quarter of 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Innovative HDV Study: A Potential Game-Changer in Viral Treatment
- Vir Biotechnology’s Promising Phase 3 Study for Chronic HDV Treatment
- Vir Biotechnology’s Phase 3 Study on HDV Treatment: A Potential Game-Changer?
- Vir Biotechnology’s Innovative Approach in HER2-Expressing Cancer Treatment: A Study Update
- Vir Biotechnology’s Promising Prostate Cancer Study: A Potential Game-Changer?